QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:TYRA

Tyra Biosciences - TYRA Stock Forecast, Price & News

$15.97
+0.12 (+0.76%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.50
▼
$16.00
50-Day Range
$7.12
▼
$15.97
52-Week Range
$4.93
▼
$16.00
Volume
82,593 shs
Average Volume
55,800 shs
Market Capitalization
$673.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Tyra Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.2% Upside
$20.00 Price Target
Short Interest
Bearish
6.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$2.62 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.36) to ($1.61) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

883rd out of 983 stocks

Pharmaceutical Preparations Industry

426th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

TYRA stock logo

About Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Stock News Headlines

March 15, 2023 | americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Trading 13.1% Higher
March 1, 2023 | finance.yahoo.com
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
March 21, 2023 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
March 1, 2023 | finance.yahoo.com
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
January 3, 2023 | finance.yahoo.com
Tyra Biosciences, Inc. (TYRA) Stock Historical Prices & Data - Yahoo Finance
December 7, 2022 | finance.yahoo.com
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
November 24, 2022 | finance.yahoo.com
How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%
November 10, 2022 | finance.yahoo.com
Tyra Biosciences to Present at Upcoming Investor Conferences
March 21, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
November 8, 2022 | finance.yahoo.com
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet
November 4, 2022 | finance.yahoo.com
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
November 2, 2022 | finance.yahoo.com
Tyra Biosciences Announces Planned Chief Financial Officer Transition
October 31, 2022 | finance.yahoo.com
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
October 18, 2022 | uk.finance.yahoo.com
Tyra Biosciences, Inc. (TYRA)
October 13, 2022 | finance.yahoo.com
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
September 8, 2022 | finance.yahoo.com
Tyra Biosciences to Participate at September 2022 Investor Conferences
September 5, 2022 | finance.yahoo.com
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
August 4, 2022 | finance.yahoo.com
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
July 29, 2022 | investing.com
Heart Test Laboratories Inc Unit (HSCS)
June 23, 2022 | seekingalpha.com
Tyra Biosciences initiated with a Buy at H.C. Wainwright
May 24, 2022 | finance.yahoo.com
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
May 5, 2022 | finance.yahoo.com
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
April 6, 2022 | finance.yahoo.com
Intrahepatic Cholangiocarcinoma Clinical Trial Pipeline Shows Rapid Progress with 20+ Companies Working to Develop Therapies, Assesses DelveInsight
March 8, 2022 | benzinga.com
Jefferies Upgrades Tyra Biosciences to Buy, Lowers Price Target to $27
March 5, 2022 | seekingalpha.com
Tyra Biosciences GAAP EPS of -$0.24
March 3, 2022 | finance.yahoo.com
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
February 22, 2022 | finance.yahoo.com
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
See More Headlines
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Company Calendar

Last Earnings
11/02/2021
Today
3/21/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYRA
CUSIP
N/A
CIK
1863127
Web
www.tyra.bio
Phone
619-728-4760
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+25.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,290,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-18.38%
Return on Assets
-17.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
48.73
Quick Ratio
48.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.31 per share
Price / Book
2.18

Miscellaneous

Outstanding Shares
42,200,000
Free Float
33,969,000
Market Cap
$673.93 million
Optionable
Not Optionable
Beta
0.83

Key Executives

  • Dr. Todd Harris Ph.D. (Age 43)
    Pres, CEO, Sec., Treasurer & Director
    Comp: $612.72k
  • Dr. Ronald V. Swanson Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $536.19k
  • Dr. Hiroomi Tada M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $519.65k
  • Mr. Daniel Bensen (Age 47)
    Co-Founder & COO
  • Lynn Scherm
    Fin. Director
  • Ms. Esther van den Boom CPA (Age 42)
    CPA, Chief Financial Officer
  • Dr. Robert L. Hudkins Ph.D. (Age 67)
    Chief Technology Officer
  • Mr. Ali D. Fawaz J.D.
    Gen. Counsel & Sec.
  • Ms. Sarah Honig
    VP of Corp. Devel. & Strategy
  • Dr. Piyush R. Patel Ph.D. (Age 57)
    Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TYRA Stock - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TYRA shares.
View TYRA analyst ratings or view top-rated stocks.

What is Tyra Biosciences' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Tyra Biosciences' shares. Their TYRA share price forecasts range from $15.00 to $25.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts.

How have TYRA shares performed in 2023?

Tyra Biosciences' stock was trading at $7.60 on January 1st, 2023. Since then, TYRA shares have increased by 110.1% and is now trading at $15.97.
View the best growth stocks for 2023 here.

When is Tyra Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our TYRA earnings forecast.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.33.

When did Tyra Biosciences IPO?

(TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

What is Tyra Biosciences' stock symbol?

Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.60%), JPMorgan Chase & Co. (0.47%), Charles Schwab Investment Management Inc. (0.23%), Bank of America Corp DE (0.05%), Morgan Stanley (0.02%) and UBS Group AG (0.01%). Insiders that own company stock include Boxer Capital, Llc and Mva Investors, Llc.
View institutional ownership trends.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyra Biosciences' stock price today?

One share of TYRA stock can currently be purchased for approximately $15.97.

How much money does Tyra Biosciences make?

Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $673.93 million. The company earns $-26,290,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How can I contact Tyra Biosciences?

Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio..

This page (NASDAQ:TYRA) was last updated on 3/21/2023 by MarketBeat.com Staff